Amylyx Pharmaceuticals, Inc.
AMLX
Rang in aandelen
#4525
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aandeelprijs
$26.87
Marktkapitalisatie
$3.37B
Verandering (1 dag)
2.01%
Verandering (1 jaar)
79.73%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Categorie
Healthcare
Dividendgeschiedenis van Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (aandelsymbool: AMLX) heeft in totaal 3 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: $1.02
Dividendrendement (TTM): 0
De som van alle dividenden (aangepast voor aandelensplitsingen) is: $1.02
Dividendrendement (TTM): 0
Dividendbetalingen voor Amylyx Pharmaceuticals, Inc. (AMLX) van 2017 tot 2026
Jaarlijkse dividendbetalingen
| Jaar | Dividend (aangepast voor aandelensplitsingen) | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Lijst van alle dividendbetalingen
| Jaar | Dividend | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal dividendbetalingen | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
